Kornimate/medical-research-clean huggingface dataset:
evaluation of the biological response to clopidogrel in patients with ischemic stroke

Conditions: Brain Ischemia; Ischemic Attack

Summary: ischemic stroke (aic) is the leading cause of non-traumatic disability in adults, the second leading cause of dementia and the third leading cause of death in france. clopidogrel is one of the recommended first line in the secondary prevention of aic non cardioembolic origin. however recurrences occur in approximately 9% of patients receiving clopidogrel. some studies in patients with coronary artery disease have made the connection between these treatment failures and non-biological response to clopidogrel. this non-biological response is found for approximately 30% to 50% of patients. several mechanisms may explain this non-response. the most accepted mechanism is pharmacokinetic. indeed, clopidogrel is a prodrug that requires intestinal absorption by p-glycoprotein (pgp) and a transformation by hepatic cytochrome into active metabolites. the genetic polymorphism of proteins involved in these two steps explain the low plasma concentration of active metabolites and thus the low efficacy of clopidogrel in some patients. a new pharmacodynamic hypothesis suggests the involvement of platelet alpha 2-adrenergic receptors. the activation of these receptors potentiates signaling pathway p2y12 receptor (channel inhibited by clopidogrel) and helps reduce platelet aggregation inhibiting response to clopidogrel.

interest in the biological response to clopidogrel in the aic is innovative because few data are available in this area. in addition to testing a new pharmacodynamic hypothesis, we also wish to study and compare other measures of platelet function methods in order to be able to use commonly in treatment decisions.

Eligibility criteria:
inclusion criteria: * consent signed * patients with non-cardioembolic aic requiring initiation of treatment with clopidogrel as usual indications * normal standard biological tests exclusion criteria: * need to continue aspirin therapy * patients with a recurrence of clopidogrel aic * patient already tacking clopidogrel * drugs interfering with the adrenergic system alpha blockers, alpha 2 receptor agonists (alpha-methyldopa) and alpha2 receptor inhibitors (mianserin, mirtazapine, yohimbine) * contra indication of clopidogrel and / or any of its excipients

Keywords: clopidogrel brain ischemia ischemic attack biological response to clopidogrel
a-protein levels in adult and pediatric brain tumor patients

Conditions: Malignant Childhood Central Nervous System Neoplasm

Summary: the purpose of this study is to evaluate the sensitivity and specificity of "a-protein" levels in patients with brain tumors. a-protein levels will be analyzed both pre and post treatment. levels in blood and/or cerebrospinal fluid (csf) will be analyzed and correlated with the underlying diagnosis and outcome.

* patients will be identified at the time of presentation to their neurologist, neurosurgeon or oncologist. * blood or cerebrospinal fluid will be collected for this study only when they are being collected for other reasons before and after each surgery. samples will also be collected after any event such as significant change in symptoms or radiographic progression. * once the patients condition has been stabilized, samples will be take at regular intervals of \>= 1 month. the duration of this study is 24 months.

Eligibility criteria:
inclusion criteria: * all patients with possible malignant or benign lesions of the central nervous system will be included. * there are no restrictions with respect to treatment protocols or prior therapy. * patients will be identified after presentation to the neurosurgical, neurological or oncologic services at participating centers. any patient with evidence of a central nervous system tumor will be eligible. individuals without evidence of cns tumors are also eligible, in order to provide blinded controls. * a signed informed consent will be requested and required for participation. * there is no age, sex, or ethnic origin restrictions in this protocol. patients who choose not to participate in the study will continue to have their regular care as defined by their treating team. patients who speak foreign languages are eligible as long a translator can be found to ensure proper consent has been obtained. exclusion criteria: there are no exclusion criteria for this study.

Keywords: a-protein level brain tumor
effects of medium-chain triglycerides on chylomicron secretion and expression of genes that regulate intestinal lipid metabolism in men with dyslipidemia associated with the metabolic syndrome

Conditions: Metabolic Syndrome X

Summary: several lines of evidence indicate that a significant proportion of cardiovascular disease (cvd) events are attributable to the presence of a cluster of metabolic abnormalities and perturbations, defined as the metabolic syndrome. it has been estimated that approximately 25% of the north american adult population is living with the metabolic syndrome. recent studies from the investigators group show that overaccumulation of atherogenic triglyceride-rich lipoproteins (trl) seen in insulin-resistant patients is partly due to increased production rate of intestinally derived apolipoprotein (apo) b-48-containing lipoproteins. this is of interest because substantial evidence exists indicating that elevated levels of intestinal lipoproteins are associated with increased cvd risk. in this regard, there is some evidence that medium-chain triglycerides (mcts) may beneficially modify lipoprotein metabolism in hypertriglyceridemic patients. however, as emphasized in the body of this grant proposal, the specific impact of mcts on the intestinal lipoprotein secretion and on expression of genes that regulate intestinal lipid absorption and chylomicron synthesis has not yet been investigated in humans. the general objective of the proposed research is to investigate the mechanisms by which mcts beneficially modify intestinal lipoprotein metabolism in patients with the metabolic syndrome. the primary hypothesis is that mct supplementation will decrease plasma levels of intestinal lipoproteins by reducing secretion of these particles.


Eligibility criteria:
inclusion criteria: * men aged between 18-60 years * waist circumference \> 102 cm * hdl-cholesterol \< 1.1 mmol/l * triglycerides \> 1.7 mmol/l * fasting blood glucose \> 6.1 mmol/l * normal blood pressure (\<130/85) exclusion criteria: * women * men \ 60 years * smokers (\> 1 cigarette/day) * body weight variation \> 10% during the last 6 months prior to the study baseline * subjects with a previous history of cardiovascular disease * subjects with type 2 diabetes * subjects with a monogenic dyslipidemia * subjects on hypertension medications or medications known to affect lipoprotein metabolism or the integrity of gastrointestinal mucosa * subjects with endocrine or gastrointestinal disorders * history of alcohol or drug abuse within the past 2 years * subjects who are in a situation or have any condition that, in the opinion of the investigator, may interfere with optimal participation in the study.
uric acid study in healthy male volunteers

Conditions: Gout; Coronary Artery Disease

Summary: this study is being conducted to examine the effect of azd6140 on the levels of certain chemicals in subjects' blood and urine.


Eligibility criteria:
inclusion criteria: * normal physical examination, vital signs, electrocardiogram (ecg) and laboratory values (unless the investigator considers an abnormality not to be clinically significant) * normal laboratory tests at screening * non-smoker (no cigarette/tobacco use for at least 6 months) exclusion criteria: * personal or family history of gout, gouty arthritis, or renal stones

Keywords: uric acid level
cardiac arrest registry of the lombardia region (lombardia care)

Conditions: Out-Of-Hospital Cardiac Arrest

Summary: the registry enroll all the patients who suffered an out-of-hospital cardiac arrest in the lombardia region with a follow-up up to ten years after the event.

the registry is an observational study which enroll all the patients who suffered an out-of-hospital cardiac arrest of any etiology in the lombardia region the follow-up of the patients is at 1 month after the event, 6 month and every year up to five years after the event.

Eligibility criteria:
inclusion criteria: * out-of-hospital cardiac arrest of any etiology in the lombardia region exclusion criteria: * in-hospital cardiac arrest

Keywords: cardiac arrest resuscitation out-of-hospital cardiac arrest cpr
thread embedding vs. electroacupuncture for post-stroke aphasia

Conditions: Post-stroke Aphasia

Summary: the goal of this clinical trial was to learn if thread embedding or electroacupuncture can treat language function impairment in patients with post-stroke aphasia, a condition affecting communication after a stroke. the main questions it aimed to answer were: does thread embedding improve overall language function more effectively than electroacupuncture, as measured by the goodglass and kaplan aphasia severity rating scale (asrs)? how do thread embedding and electroacupuncture compare in improving specific language skills, such as motor speech, sensory language, reading, and naming, as assessed by the boston diagnostic aphasia examination (bdae)? researchers compared thread embedding (te group) to electroacupuncture (ea group) to see if thread embedding provides better or similar effects on language recovery. participants: underwent a 30-day intervention with language assessments at the start and end of the period. were randomly assigned to either the thread embedding group, receiving treatment every 10 days, or the electroacupuncture group, receiving daily 20-minute sessions.

this study was designed as a randomized, open-label, parallel-group trial conducted at the traditional medicine hospital in dak lak, vietnam. it received ethical approval from the biomedical research ethic committee at the university of medicine and pharmacy at ho chi minh city (approval no. 739/hđđđ-đhyd, dated december 14, 2021). the interventions were delivered by certified traditional medicine practitioners following strict protocols (stricta 2010). catgut thread embedding (te group): participants received thread embedding at the ex-hn21 acupoint. electroacupuncture (ea group): participants underwent daily 20-minute sessions in 30 days. language function was assessed using standardized tools, and data were analyzed with r. statistical tests (chi-square, t-tests) compared baseline characteristics and outcomes, with a significance level of p \< 0.05.

Eligibility criteria:
inclusion criteria: * diagnosed with post-stroke aphasia (severity levels 0-4 on the goodglass and kaplan scale) * aged 18 years or older * fluent in vietnamese * alert and mentally competent (no psychiatric or neurological disorders affecting communication) * no pre-existing speech or language disorders * willing to participate and provide signed informed consent * treated as inpatients at the traditional medicine hospital, dak lak exclusion criteria: * severe physical exhaustion or skin ulcers/infections at intervention sites * presence of a pacemaker * allergy to catgut threads * post-stroke patients awaiting cranioplasty * complex disease progression requiring alternative treatments during the study (data analyzed as treatment failures)

Keywords: aphasia stroke catgut thread embedding electroacupuncture speech-language rehabilitation
treatment of meditoxin® in female patients with idiopathic overactive bladder

Conditions: Overactive Bladder

Summary: to investigate the safety of meditoxin in female subjects with idiopathic overactive bladder compared with botox


Eligibility criteria:
inclusion criteria: * female aged more than 20 years * subject who has symptoms of overactive bladder for a period of at least 6 months immediately prior to screening exclusion criteria: - patient not appropriate for participating in this study according to the investigator's opinion
pilot clinical performance of a silicone hydrogel lens for up to six nights of extended wear

Conditions: Refractive Errors; Myopia; Hyperopia

Summary: the purpose of this clinical study is to evaluate the on-eye performance of an investigational soft contact lens compared to a commercially available soft contact lens when worn continuously for up to 1 week.

subjects will be randomized to wear the investigational contact lens in 1 eye and the commercially available contact lens in the other eye. subjects will be expected to attend 3 scheduled study visits: day 1 screening/baseline/dispense; day 2 follow-up within 4 hours of awakening (after the first night of sleeping); and week 1 follow-up/exit. the expected duration of exposure to each of the study lenses for all randomized, completed subjects was approximately 7 days / 6 nights of wear.

Eligibility criteria:
key inclusion criteria: * able to understand and sign an irb/iec approved informed consent form. * successful wear of spherical soft contact lenses in both eyes during the past 3 months for a minimum of 5 days/week and in an extended wear modality at least 1 night/week. * best corrected visual acuity of 20/25 or better in each eye. * other protocol-specified inclusion criteria may apply. key exclusion criteria: * any condition, use of medications, or surgery that could contraindicate contact lens wear, as determined by the investigator. * any habitual wear of biofinity contact lenses. * pregnant or breast-feeding. * other protocol specified exclusion criteria may apply.

Keywords: extended wear contact lens overnight wear vision correction contralateral wear
assessment of new blood culture methods on the microbiological documentation of febrile neutropenia

Conditions: Febrile; Neutropenia; Post-chemotherapy

Summary: febrile neutropenia are microbiologically documented in only 30% of the cases, and almost exclusively by blood cultures. the reasons for this low documentation are likely multiple: (1) some of these fevers are of non-infectious origin. (2) the bacterial inoculum present in the blood may be low and consequently undetectable by conventional blood cultures. the primary objective of the study is to assess new blood culture procedures and technics, in order to improve the diagnostic yield of blood cultures during febrile neutropenic episodes.

evaluation criteria are 1) proportion of microbiologically documented infections 2) time elapsed from bed side sampling to microbiological diagnostic, in case of positive sample. the assessed procedures included a large volume of blood, an early incubation made possible by the availability of a culture device in the hematology department, an early warning in case of positive blood culture, bacterial dna detection in blood, and an early identification of the positive strains and their resistance profile. we hypothesize that the combination of these different procedures will improve the proportion of microbiologically blood culture from 30 to 45%. one hundred and 20 episodes of febrile neutropenia are necessary to achieve this goal.

Eligibility criteria:
inclusion criteria: * age \> 18 y * first episode of febrile neutropenia during a given neutropenic phase * pmn \< 500/mm3, chemotherapy-induced * fever \> 38°c twice, or \< 38°3c once * signed informed consent exclusion criteria: - patient already receiving empirical or therapeutic antibacterial after their first episode of febrile neutropenia

Keywords: febrile neutropenia blood culture bacteremia bacterial dna testing
post-first progression use of bevacizumab in metastatic colorectal cancer (mcrc)

Conditions: Metastatic Colorectal Cancer

Summary: bevacizumab beyond progression has been proven to be safe in the community setting (brite) and in the post-marketing study (beat), and confirmed its efficacy and safety in the first line with all regimens of chemotherapy. a total of 1,953 patients were treated in brite. at median follow-up of 17.5 mo, there were 1,369 1st pd and 839 deaths. among patients with 1st pd, 65.2% received any 2nd-line chemotherapy, 34.8% received cetuximab, and 53.8% received bbp. in a multivariate analysis, bevacizumab beyond first progression and exposure to any 2nd-line chemotherapy were independently associated with increased overall survival (both p \< 0.0001). bevacizumab beyond progression appears to be associated with longer overall in brite. the investigators planned a prospective study to prove this phenomenon of bevacizumab beyond progression.

patients should have been treated with bevacizumab plus chemotherapy as a 1st line treatment, and after 1st progression, these patients will be accrued in this study of bevacizumab plus chemotherapy as a 2nd line treatment, and the combined chemotherapy will be chosen by physician's decision in consider with previous chemotherapy.

Eligibility criteria:
inclusion criteria: * histologically documented colorectal adenocarcinoma * progression during first-line bevacizumab containing chemotherapy within 3 months * no serious toxicity to bevacizumab of 1st line treatment * unresectable metastases * uni-dimensional measurable lesion(s) by recist * age over 18 years old * ecog 0-2 * adequate organ functions by clinical laboratory exams exclusion criteria: * other tumor type than adenocarcinoma * cns metastases * gi bleeding * hypersensitivity to any of chemotherapeutic agents * prior use of cetuximab or other targeted agents other than bevacizumab * major surgery within 6 weeks * other serious illness

Keywords: colorectal cancer bevacizumab
study to evaluate the efficacy and safety of sandostatin lar at high dose or in combination either with gh-receptor antagonist or dopamine-agonist in acromegalic patients

Conditions: Acromegaly

Summary: this study will assess the efficacy of 8 months treatment of sandostatin® lar® high dose monotherapy or sandostatin® lar® high dose in combination either with growth hormone antagonist or dopamine agonist to control biochemical parameters (gh and insulin-like growth factor i \[igf i\]) of acromegalic patients not achieving biochemical normalization at conventional regimen.


Eligibility criteria:
inclusion criteria: • patient with a biochemically documented active acromegaly, not adequately controlled by somatostatin-analogues at conventional regimen as follow : mean 1-hour gh \> 2.5 ng/ml and elevated igf-1 (adjusted for age and gender) * patient with reduction of either mean fasting gh at least 50% or igf-1 at least 25% from any medical pretreatment level * patient currently receiving somatostatin-analogues at conventional regimen (maximum registered dose) for at least 6 months before inclusion exclusion criteria: * newly diagnosed or previously medically untreated acromegalic patient * concomitant treatment with gh-receptor antagonist * concomitant treatment with dopamine-agonist * symptomatic cholelithiasis or choledocolithiasis * liver transaminases (alt, ast) elevated, but \> 3 times upper normal limit (according to local laboratory) * previous gamma-knife radiotherapy for treatment of acromegaly * compression of the optic chiasm causing visual field defect * any medical conditions contraindicated in the summary of product characteristic (spc) of all drugs other protocol-defined inclusion/exclusion criteria may apply

Keywords: sandostatin lar high dose gh-receptor antagonist combination with dopamine-agonist acromegalic patients octreotide acetate somavert dostinex pegvisomant cabergoline not adequately controlled active acromegaly
incisional negative pressure therapy to prevent animal induced wound infection

Conditions: Injury Caused by Animal Bites; Wound Infection

Summary: animal injuries are a significant public health issue, with the most common being bites or scratches from cats and dogs. every year, over 40 million people in china are bitten or scratched by cats and dogs, which can lead to wound infections and even systemic complications, with infection rates ranging from 10% to 80%. however, there is still no better way to reduce wound infection rates in current clinical studies and guidelines. incisional negative pressure wound therapy (inpwt) is a new wound treatment technology developed in recent years. it creates a negative pressure environment on sutured or closed wounds, helps to fix the edges of the incision together, reduce lateral tension on the wound, stimulate blood perfusion at the edge of the wound, remove fluid from the wound, and act as an external pollution barrier. inpwt has been widely used for postoperative wound healing in surgery, but there is currently a lack of effective clinical trials on its ability to prevent wound infections caused by animal injuries and promote wound healing. this study aims to apply inpwt technology to the wounds of patients with rabies grade iii exposure who underwent primary suturing, and compare it with wounds covered with ordinary gauze after previous primary suturing to determine whether it can help reduce postoperative incision infection rates and promote wound healing. this will provide high-quality clinical evidence for the widespread use of wound management in rabies grade iii exposure patients in the future.


Eligibility criteria:
inclusion criteria: * limds injuries caused by animals, first or second animal injury to grade iii exposed patients, with deep wounds reaching the fat layer, tendons, and even penetrating injuries. * patients with wounds\>2cm and severe injuries that even require surgical treatment. exclusion criteria: * missing or incomplete follow-up data within 30 days. * patients who have been infected with wounds or have been injured for more than 8 hours before seeking medical attention. * acupuncture like wound (\<2mm). * patients with whole skin detachment.

Keywords: animal bite injury incision negative pressure treatment technology wound infection rate
self-help parent training for conduct problems in children

Conditions: Behavioral Symptoms

Summary: this project will introduce a self-help parent training programme for families on national health service (nhs) waiting lists for child mental health services. it will examine whether access to treatment can be increased by providing an intervention that requires fewer resources and by releasing clinician time for more serious cases. this intervention will be tested in a randomised, controlled trial in which 35 subjects will receive treatment immediately and 35 will receive treatment after waiting for 10 weeks. all families will also complete questionnaires before and after the 10 week study period in order to measure changes in child behaviour, parenting, and parental mental health. cost-effectiveness of this programme will also be analysed. intention-to-treat analyses will be conducted.


Eligibility criteria:
inclusion criteria: * families on waiting lists and child and adolescent mental health services clinics with children aged 2-5. * scores in the clinical range on a standardised measure of child behaviour problems. * at least one parent in each family must be literate, fluent english speakers to participate because the self-administered intervention will primarily consist of written instructions and information in english. exclusion criteria: * clients whose children score below a clinical cut-off score on a standardised measure of child behaviour problems. this is to ensure that participants are appropriate for an intervention aiming to reduce behaviour problems. * non-english speakers or those who are unable to read cannot be included because reading english is required to complete the self-administered intervention. * children or parents with severe disabilities and children with a developmental disorder (e.g., autism) will be excluded because the version of the parent training programme that will be implemented is not designed for families with these types of problems. * children who live with a temporary caregiver will be excluded because the intervention is designed for full-time parents and follow-up will be after one year. * children or parents who are currently receiving treatment for psychological problems will be excluded because outcomes may be influenced by interventions not affiliated with this project.

Keywords: behavior conduct child parenting self-help media-based